Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community
Top Cited Papers
- 31 August 2009
- journal article
- research article
- Published by Elsevier BV in Atherosclerosis
- Vol. 205 (2), 385-390
- https://doi.org/10.1016/j.atherosclerosis.2009.01.001
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisThe New England Journal of Medicine, 2008
- Evaluation of Gentian cystatin C reagent on Abbott Ci8200 and calculation of glomerular filtration rate expressed in mL/min/1.73 m2from the cystatin C values in mg/LScandinavian Journal of Clinical and Laboratory Investigation, 2007
- A Comparison of Three Different Methods to Evaluate Endothelium-Dependent Vasodilation in the ElderlyArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Calcium, Phosphorus, Parathyroid Hormone, and Cardiovascular Disease in Hemodialysis Patients: The USRDS Waves 1, 3, and 4 StudyJournal of the American Society of Nephrology, 2005
- Mineral Metabolism, Mortality, and Morbidity in Maintenance HemodialysisJournal of the American Society of Nephrology, 2004
- FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate HomeostasisJournal of Bone and Mineral Research, 2004
- Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteersKidney International, 2003
- Cardiovascular Calcifications in Uremic PatientsJournal of the American Society of Nephrology, 2003
- Arterial Calcifications, Arterial Stiffness, and Cardiovascular Risk in End-Stage Renal DiseaseHypertension, 2001
- Methodological aspects of the evaluation of endothelium‐dependent vasodilatation in the human forearmClinical Physiology and Functional Imaging, 1998